Skip to main content
Kisqali patient portrayal.

MONALEESA-3 safety profile

KISQALI + fulvestrant in 1L/2L postmenopausal patients

References: 1. Tripathy D, Im S-A, Colleoni M, et al. Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial. Lancet Oncol. 2018;19(7):904-915. doi:10.1016/S1470-2045(18)30292-4 2. Slamon DJ, Neven P, Chia S, et al. Phase III randomized study of ribociclib and fulvestrant in hormone receptor–positive, human epidermal growth factor receptor 2–negative advanced breast cancer: MONALEESA-3. J Clin Oncol. 2018;36(24):2465-2472. doi:10.1200/JCO.2018.78.9909 3. Data on file. CLEE011A2301. Novartis Pharmaceuticals Corp; 2016. 4. Kisqali. Prescribing information. Novartis Pharmaceuticals Corp. 5. Yardley DA, Yap YS, Azim HA, et al. Pooled exploratory analysis of survival in patients with HR+/HER2− advanced breast cancer and visceral metastases treated with ribociclib + endocrine therapy in the MONALEESA trials. Poster presented at: ESMO Congress 2022; September 9-13, 2022; Paris, France. Poster 205P.